Corvus Pharma's Q2 earnings were in line with analyst expectations, which is generally a positive sign. However, the company is still reporting losses, which could limit the positive impact on the stock price. The 22.22% improvement from the same period last year indicates that the company's financial situation is improving, which could have a positive impact on the stock price in the long term.